| # | Title | Journal | Year | Citations |
|---|
| 1 | Metal complexes in cancer therapy – an update from drug design perspective | Drug Design, Development and Therapy | 2017 | 668 |
| 2 | Current development of biodegradable polymeric materials for biomedical applications | Drug Design, Development and Therapy | 2018 | 604 |
| 3 | Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery | Drug Design, Development and Therapy | 2016 | 471 |
| 4 | Animal models of ischemic stroke and their application in clinical research | Drug Design, Development and Therapy | 2015 | 361 |
| 5 | Eteplirsen in the treatment of Duchenne muscular dystrophy | Drug Design, Development and Therapy | 2017 | 334 |
| 6 | 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications | Drug Design, Development and Therapy | 2013 | 317 |
| 7 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway | Drug Design, Development and Therapy | 2015 | 309 |
| 8 | Molecular mechanisms of cisplatin resistance in cervical cancer | Drug Design, Development and Therapy | 2016 | 291 |
| 9 | Update on developments with SGLT2 inhibitors in the management of type 2 diabetes | Drug Design, Development and Therapy | 2014 | 279 |
| 10 | Leishmaniasis in humans: drug or vaccine therapy? | Drug Design, Development and Therapy | 2018 | 256 |
| 11 | Current and emerging drugs for the treatment of inflammatory bowel disease | Drug Design, Development and Therapy | 2011 | 232 |
| 12 | Drugs in development for toxoplasmosis: advances, challenges, and current status | Drug Design, Development and Therapy | 2017 | 221 |
| 13 | Linezolid: a review of its properties, function, and use in critical care | Drug Design, Development and Therapy | 2018 | 221 |
| 14 | Metformin: a review of its potential indications | Drug Design, Development and Therapy | 2017 | 218 |
| 15 | Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease | Drug Design, Development and Therapy | 2017 | 217 |
| 16 | Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date | Drug Design, Development and Therapy | 2014 | 215 |
| 17 | Bispecific antibodies: design, therapy, perspectives | Drug Design, Development and Therapy | 2018 | 211 |
| 18 | Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey | Drug Design, Development and Therapy | 2011 | 201 |
| 19 | Animal models and therapeutic molecular targets of cancer: utility and limitations | Drug Design, Development and Therapy | 2014 | 196 |
| 20 | Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells | Drug Design, Development and Therapy | 2016 | 191 |
| 21 | Albumin-bound paclitaxel in solid tumors: clinical development and future directions | Drug Design, Development and Therapy | 2015 | 189 |
| 22 | <p>Minoxidil and its use in hair disorders: a review</p> | Drug Design, Development and Therapy | 2019 | 187 |
| 23 | Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures | Drug Design, Development and Therapy | 2021 | 186 |
| 24 | <p>Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives</p> | Drug Design, Development and Therapy | 2020 | 176 |
| 25 | Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date | Drug Design, Development and Therapy | 2014 | 171 |
| 26 | Apatinib for molecular targeted therapy in tumor | Drug Design, Development and Therapy | 2015 | 169 |
| 27 | Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond | Drug Design, Development and Therapy | 2011 | 165 |
| 28 | Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review | Drug Design, Development and Therapy | 2016 | 164 |
| 29 | Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues | Drug Design, Development and Therapy | 2015 | 160 |
| 30 | Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment | Drug Design, Development and Therapy | 2013 | 157 |
| 31 | Update on taxane development: new analogs and new formulations | Drug Design, Development and Therapy | 2012 | 155 |
| 32 | Organelle targeting: third level of drug targeting | Drug Design, Development and Therapy | 2013 | 154 |
| 33 | Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Drug Design, Development and Therapy | 2015 | 150 |
| 34 | <p>Ketamine and depression: a narrative review</p> | Drug Design, Development and Therapy | 2019 | 149 |
| 35 | Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Drug Design, Development and Therapy | 2014 | 146 |
| 36 | <p>In-vitro blood-brain barrier models for drug screening and permeation studies: an overview</p> | Drug Design, Development and Therapy | 2019 | 145 |
| 37 | <p>Potential of Nanoparticles as Permeation Enhancers and Targeted Delivery Options for Skin: Advantages and Disadvantages</p> | Drug Design, Development and Therapy | 2020 | 145 |
| 38 | ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile | Drug Design, Development and Therapy | 2010 | 142 |
| 39 | Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro | Drug Design, Development and Therapy | 2018 | 141 |
| 40 | Modulation of neurotrophic signaling pathways by polyphenols | Drug Design, Development and Therapy | 2016 | 139 |
| 41 | Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial | Drug Design, Development and Therapy | 2015 | 137 |
| 42 | Osteoporosis – a current view of pharmacological prevention and treatment | Drug Design, Development and Therapy | 2013 | 136 |
| 43 | Emerging options for the management of scorpion stings | Drug Design, Development and Therapy | 2012 | 135 |
| 44 | Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies | Drug Design, Development and Therapy | 2015 | 135 |
| 45 | The new era of nanotechnology, an alternative to change cancer treatment | Drug Design, Development and Therapy | 2017 | 135 |
| 46 | <p>Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes</p> | Drug Design, Development and Therapy | 2019 | 133 |
| 47 | Animal models of ulcerative colitis and their application in drug research | Drug Design, Development and Therapy | 2013 | 132 |
| 48 | CXCR4 in breast cancer: oncogenic role and therapeutic targeting | Drug Design, Development and Therapy | 2015 | 132 |
| 49 | The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design | Drug Design, Development and Therapy | 2021 | 127 |
| 50 | Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway | Drug Design, Development and Therapy | 2018 | 126 |
